Corcept Therapeutics Inc (CORT)
ROE
Obliczenia
|
2023/Q4 (31 gru 2023) |
2023/Q3 (30 wrz 2023) |
2023/Q2 (30 cze 2023) |
2023/Q1 (31 mar 2023) |
2022/Q4 (31 gru 2022) |
2022/Q3 (30 wrz 2022) |
2022/Q2 (30 cze 2022) |
2022/Q1 (31 mar 2022) |
||
|---|---|---|---|---|---|---|---|---|---|
| Zysk netto (ttm) | w tys. USD | 106 140 | 91 386 | 94 616 | 94 500 | 101 418 | 116 870 | 112 733 | 111 844 |
| Kapitał własny | w tys. USD | 506 705 | 461 679 | 421 614 | 529 584 | 501 842 | 473 364 | 442 326 | 407 811 |
| ROE | 20,95% | 19,79% | 22,44% | 17,84% | 20,21% | 24,69% | 25,49% | 27,43% |
2023/Q4 obliczenia
ROE = Zysk netto (ttm) ÷ Kapitał własny
= $106 140K ÷ $506 705K
= 20,95%
Analiza porównawcza
2023/Q4
Nazwa spółki
Symbol
ROE
Corcept Therapeutics Inc
CORT
20,95%
Amphastar Pharmaceuticals Inc
AMPH
21,51%
Catalyst Pharmaceuticals Inc
CPRX
18,41%
Harmony Biosciences Holdings Inc
HRMY
27,59%
Ironwood Pharmaceuticals Inc
IRWD
—
Myriad Genetics, Inc.
MYGN
-33,62%
Pacira BioSciences Inc
PCRX
4,82%
Prestige Consumer Healthcare Inc
PBH
-5,04%
Schrodinger Inc
SDGR
7,42%
Supernus Pharmaceuticals Inc
SUPN
0,14%
Xencor Inc
XNCR
-18,85%